vs
Side-by-side financial comparison of Broadstone Net Lease, Inc. (BNL) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $121.4M, roughly 1.5× Broadstone Net Lease, Inc.). Broadstone Net Lease, Inc. runs the higher net margin — 38.2% vs 1.6%, a 36.6% gap on every dollar of revenue. On growth, Broadstone Net Lease, Inc. posted the faster year-over-year revenue change (11.7% vs 5.0%). Over the past eight quarters, Broadstone Net Lease, Inc.'s revenue compounded faster (7.1% CAGR vs -0.2%).
Broadstone Net Lease, Inc. is a real estate investment trust (REIT) that acquires, owns, and manages a diversified portfolio of single-tenant commercial real estate assets across the United States. Its portfolio covers key segments including industrial facilities, healthcare properties, retail locations, and office spaces, all leased to tenants under long-term net lease agreements.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BNL vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $121.4M | $177.4M |
| Net Profit | $46.4M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 52.2% | 3.9% |
| Net Margin | 38.2% | 1.6% |
| Revenue YoY | 11.7% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.24 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $121.4M | $177.4M | ||
| Q4 25 | $118.3M | $196.9M | ||
| Q3 25 | $114.2M | $179.5M | ||
| Q2 25 | $113.0M | $181.1M | ||
| Q1 25 | $108.7M | $168.9M | ||
| Q4 24 | $112.1M | $187.3M | ||
| Q3 24 | $108.4M | $168.6M | ||
| Q2 24 | $105.9M | $178.0M |
| Q1 26 | $46.4M | $2.9M | ||
| Q4 25 | $33.1M | — | ||
| Q3 25 | $26.5M | $5.4M | ||
| Q2 25 | $20.2M | $-4.8M | ||
| Q1 25 | $16.7M | $4.8M | ||
| Q4 24 | $26.4M | — | ||
| Q3 24 | $35.6M | $-143.5M | ||
| Q2 24 | $35.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | 52.2% | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | -82.8% | ||
| Q2 24 | — | 15.9% |
| Q1 26 | 38.2% | 1.6% | ||
| Q4 25 | 28.0% | — | ||
| Q3 25 | 23.2% | 3.0% | ||
| Q2 25 | 17.8% | -2.7% | ||
| Q1 25 | 15.4% | 2.8% | ||
| Q4 24 | 23.5% | — | ||
| Q3 24 | 32.8% | -85.1% | ||
| Q2 24 | 33.4% | 10.6% |
| Q1 26 | $0.24 | $0.07 | ||
| Q4 25 | $0.17 | $0.05 | ||
| Q3 25 | $0.14 | $0.12 | ||
| Q2 25 | $0.10 | $-0.11 | ||
| Q1 25 | $0.09 | $0.10 | ||
| Q4 24 | $0.13 | $0.38 | ||
| Q3 24 | $0.19 | $-3.11 | ||
| Q2 24 | $0.19 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.3M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.0B | $653.9M |
| Total Assets | $5.8B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $20.3M | $144.3M | ||
| Q4 25 | $30.5M | $238.4M | ||
| Q3 25 | $82.0M | $246.3M | ||
| Q2 25 | $20.8M | $445.9M | ||
| Q1 25 | $9.6M | $493.6M | ||
| Q4 24 | $14.8M | $484.6M | ||
| Q3 24 | $9.0M | $453.8M | ||
| Q2 24 | $18.3M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $372.2M | ||
| Q3 25 | $2.4B | $376.7M | ||
| Q2 25 | $2.1B | $580.5M | ||
| Q1 25 | $2.0B | $583.4M | ||
| Q4 24 | $1.9B | $585.3M | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $1.9B | — |
| Q1 26 | $3.0B | $653.9M | ||
| Q4 25 | $2.9B | $693.1M | ||
| Q3 25 | $2.9B | $727.2M | ||
| Q2 25 | $2.9B | $757.8M | ||
| Q1 25 | $2.9B | $798.5M | ||
| Q4 24 | $3.0B | $778.3M | ||
| Q3 24 | $3.0B | $749.6M | ||
| Q2 24 | $3.1B | $879.3M |
| Q1 26 | $5.8B | $1.2B | ||
| Q4 25 | $5.7B | $1.3B | ||
| Q3 25 | $5.5B | $1.3B | ||
| Q2 25 | $5.3B | $1.5B | ||
| Q1 25 | $5.2B | $1.6B | ||
| Q4 24 | $5.2B | $1.6B | ||
| Q3 24 | $5.3B | $1.5B | ||
| Q2 24 | $5.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.87× | 0.54× | ||
| Q3 25 | 0.82× | 0.52× | ||
| Q2 25 | 0.73× | 0.77× | ||
| Q1 25 | 0.68× | 0.73× | ||
| Q4 24 | 0.64× | 0.75× | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 0.62× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BNL
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
